Levosimendan: 30 years of data and developments | Acute and Advanced Heart Failure | epgonline.org

Professor Pölzl discusses levosimendan and the REFALS 3 trial, which will evaluate the impact of levosimendan on respiratory function in patients with acute lateral sclerosis (ALS).